Noble Financial Has Bullish Forecast for UNCY Q3 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at Noble Financial upped their Q3 2026 earnings per share estimates for shares of Unicycive Therapeutics in a research report issued on Tuesday, March 31st. Noble Financial analyst R. Leboyer now forecasts that the company will earn $0.79 per share for the quarter, up from their prior forecast of $0.74. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

A number of other research firms have also recently issued reports on UNCY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday. Guggenheim reissued a “buy” rating on shares of Unicycive Therapeutics in a report on Tuesday, December 30th. Finally, Westpark Capital initiated coverage on shares of Unicycive Therapeutics in a research report on Thursday, February 19th. They issued a “buy” rating for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Unicycive Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.33.

Unicycive Therapeutics Stock Performance

Shares of UNCY stock opened at $6.58 on Wednesday. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00. The stock has a market capitalization of $141.40 million, a PE ratio of -3.03 and a beta of 1.82. The stock’s fifty day moving average is $6.66 and its 200-day moving average is $5.77.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in UNCY. JPMorgan Chase & Co. raised its position in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares during the last quarter. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics in the second quarter valued at about $55,000. Vanguard Group Inc. increased its position in Unicycive Therapeutics by 8.7% in the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after purchasing an additional 52,925 shares during the period. Squarepoint Ops LLC acquired a new stake in Unicycive Therapeutics in the third quarter worth about $512,000. Finally, Citadel Advisors LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter worth about $182,000. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.